KIR2DL3 and glioblastoma: In BG7 GBM cells that were highly sensitive for NK cell-mediated lysis (Figures 4A,B,D), the inhibitory signals of intermediate strength from licensed KIR2DL3 against cognate ligand HLA-C*07:01 (also present in BG7 cells) might have been overridden by further lack of KIR2DL2 in these donors’ NK cells that also possessed several non-licensed, potentially hyporesponsive KIR subsets (Table 3).